Pricing

Following the backlash over the Turing Pharma drug price rise, the healthcare industry can not afford to ignore the signals and must carefully consider what to do next, writes Meg Alexander.

A slightly different take on this Turing Pharmaceuticals/Martin Shkreli business?

Kaiser’s August healthcare poll results should put all on high alert given public sentiment and the rhetoric of the political season. Ed Schoonveld sounds the alarm and offers four initiatives to stall the surge towards government intercession on escalating prices.

The clocks are ticking for Express Scripts, writes Stephen E. Littlejohn. Having achieved formidable “size and scale,” how will the nation’s largest pharmacy benefit manager synchronize with value-based health care?

Learnings gleaned from our annual EAB meeting, hosted this year by Dr. David Nash, Dean of the Thomas Jefferson University School of Population Health.

Making sense of the new cost-containment model and value-for-money conundrums like those in the HCV space.

Recent developments in the pharmaceutical industry give the strong impression that both payers and industry are struggling to understand what represents “value” to customers, writes Ed Schoonveld.

Pharm Exec speaks with IMS Health's John Daly and John Moran about new ways IDNs are impacting the healthcare decision landscape and the advantages of what they call “smart targeting”.

In the shift from volume to value as the underlying driver in health care, pharma has only scratched the surface of possibility for new and non-traditional arrangements with a broader variety of partners with healthcare interests, writes Cliff Kalb.

CMS's Part B data release has increased transparency but has also resulted in potentially misplaced scrutiny of high-billing doctors. Ben Scher, Kathleen Twigg, and Andrew Huson take a closer look.

Why Real World Evidence (RWE) is here to stay, and what you need to do to integrate it into your business strategy as painlessly as possible.

Data has become as important as the drug in driving success in healthcare.

The strict regulatory divide between market authorization and price reimbursement iscrumbling in the US. Is industry prepared to adapt or challenge?

The Deficit Reduction Act was designed to save the government money on Medicaid. But it also has the potential to change the very way pharma companies conduct business-if they can just figure it out.